Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review

Notten, Pascale; Cate, Hugo Ten; Cate‐Hoek, Arina J. ten

doi:10.1111/jth.15197

Cited by 25 publications

(3 citation statements)

References 74 publications

(1,121 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As vein stenting was well verified for IFDVT patients with long-term patency varied from 57% to 92%, 6,7,14 many efforts were made in the management of ISR, including various medications 15,16 and endovascular interventions. 9,17 In this study, we conducted a histologic evaluation based on arterial and venous ISR patients and found similar α-SMA and FSP-1 coexpression patterns, suggesting the possibility of DCB application in venous ISR cases.…”

Section: Discussionmentioning

confidence: 99%

Drug‐coated balloon therapy for in‐stent restenosis in patients with iliofemoral deep vein thrombosis: A single‐arm observational study

Lei,

Pu,

Zhang

et al. 2024

Cathet Cardio Intervent

View full text Add to dashboard Cite

BackgroundIliofemoral deep vein thrombosis (IFDVT) causes severe symptoms and affect the quality of life to a great extent. Endovascular thrombectomy and stent implantation have been a feasible strategie to alleviate the signs and symptoms of IFDVT. However, venous in‐stent restenosis (ISR) has become an emerging non‐negligible problem.MethodsTo evaluate the histological characteristics of venous ISR, neointima of arterial and venous ISR patients were collected and examed. To explore the effect of drug‐coated balloon (DCB) on venous ISR lesions, we conducted a single‐center retrospective case series study involving IFDVT patients with ISR after venous stenting who were treated with paclitaxel‐coated balloon dilatation.ResultsWe found a collagen‐rich matrix but not elastin, as well as fewer cells and less neovascularization in venous intimal hyperplasia compared with neointima in arteries. Thirteen IFDVT patients were involved in the study, with average preoperative stenosis degree of 87.69% ± 13.48%. After intervention, the stenosis degree was significantly reduced to 14.6% ± 14.36% immediately (p < 0.0001) and to 16.54% ± 15.73% during follow‐up (p < 0.0001). During follow‐up, the VEINES‐QOL scores (p < 0.0001), VEINES‐Sym scores (p < 0.0001), and Villalta scores (p = 0.04) of patients was improved significantly compared with those before intervention. No major adverse events were observed.ConclusionsThe use of DCB may have a positive effect in the treatment of venous ISR by targeting intimal hyperplasia. Moreover, the application of DCB dilatation in IFDVT stenting patients with ISR is deemed safe and effective.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug‐coated balloon therapy for in‐stent restenosis in patients with iliofemoral deep vein thrombosis: A single‐arm observational study

Lei,

Pu,

Zhang

et al. 2024

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…14,30 However, the use of anticoagulants in this setting varies widely. [38][39][40] It is not surprising, therefore, that several other consensus attempts have been made on this aspect of stent management. 39 The participants in our Delphi process agreed that anticoagulation should be started early or immediately after stent implantation, that anticoagulation should initially be performed with low-molecular-weight heparins, and that anticoagulation should be maintained long term (at least the first 6 months) if the bleeding risk is low or moderate and if the DVT is idiopathic or caused by a minor transient risk factor.…”

Section: Discussionmentioning

confidence: 99%

Optimizing Venous Stenting: Consensus Recommendations for Enhanced Management of Lower Extremity Deep Vein Thrombosis

Trujillo-Santos,

Demelo-Rodríguez,

Bravo de Laguna-Taboada

et al. 2024

Semin Thromb Hemost

View full text Add to dashboard Cite

Introduction Deep vein thrombosis (DVT) poses a complex challenge and often leads to postthrombotic syndrome (PTS), a debilitating complication. The emergence of venous stents offers a potential preventive avenue against this complication. This study aimed to provide consensus recommendations on the use of venous stent for DVT. Materials and Methods From June to July 2023, 20 internal medicine, angiology and vascular surgery, and vascular and interventional radiology experts were involved in the Delphi process. Thirty-one recommendations, categorized into three thematic areas, were rigorously evaluated: indications for stent use, stent selection and placement, and monitoring and prevention of complications. Agreement was evaluated using a Likert scale, with consensus defined as agreement by two-thirds of the participants. Results Consensus was reached for 23 (74.2%) of 31 recommendations. The agreement was centered on considerations, such as stent placement in specific acute DVT scenarios, emphasizing pivotal stent characteristics. However, there were divergences in the recommended stent length to prevent migration and stent characteristics based on iliocaval bifurcation morphology. Notably, there was no consensus on whether patients with DVT caused by a major transient risk factor need more than 3 months of anticoagulation therapy or whether aspirin should be added to anticoagulant treatment after venous stenting. Conclusions These consensus recommendations offer practical insights into optimizing venous stent use to prevent PTS in DVT patients. Addressing the critical aspects of stent selection, placement, and postprocedural care, these recommendations contribute to clinical decision-making. The identified divergences underscore the importance of consensus and thus indicate the need for further investigation.

show abstract

“…За даними сучасних наукових досліджень, а саме як зазначають V. Orhurhu et al (2021), P. Notten et al (2021) та інші, різноманітні прояви хронічної венозної недостатності (ХВН) є найбільш розповсюдженою патологією, що належить до групи серцево-судинних захворювань [11,12,19]. Кількість уперше діагностованих хворих на ХВН продовжує постійно зростати у всьому світі.…”

Section: вступunclassified

Phleboprotective effect of Saponaria officinalis herbs extract under conditions of experimental venostasis

Tsubanova,

Voloshchuk,

Zastryzhna

2024

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

Annotation. Chronic venous insufficiency has held the leading positions for the last 50 years in the general list of human diseases and has a significant specific weight in the group of cardiovascular pathologies. The number of drugs with phleboprotective effect on the pharmaceutical market of Ukraine and the world is extremely limited. Medicinal plant raw materials with venoconstrictor, antioxidant action and the ability to prevent blood clots can be considered as a promising object as a new phleboprotective medicinal product. The aim of this work was to study the effect of Saponaria officinalis herb extract under conditions of experimental venostasis. Experimental male rats weighing 180-220 g were simulated venostasis by placing a ligature on the tail vein. The dynamics of tail volume increase during 6 hours and the involution of edema after 1, 2, 17 and 24 hours were recorded, as well as blood coagulation time, prothrombin and thrombin time were determined. The researched extract of the common soapwort herb (ECSH) was administered intragastrically at a dose of 20 mg/kg. The comparison drug Eskuvit at a dose of 7.2 mg/kg according to escin. Statistical analysis was performed using descriptive statistics using Microsoft Excel and the Statistica 6.0 package. Convergences were considered favorable at p≤0.05. It was established that the therapeutic and prophylactic administration of ECSH at a dose of 20 mg/kg probably reduces the clinical indicators of transudative edema, which developed as a result of acute venostasis. Administration of ECSH normalizes indicators of general blood coagulation to the level of physiological limits. Therefore, the therapeutic and prophylactic administration of ECSH at a dose of 20 mg/kg during experimental venostasis with transudative edema and increased thrombus formation exerts a powerful phleboprotective effect, which statistically significantly exceeds the effectiveness of the comparison drug Eskuvit. Further studies of anti-inflammatory, membrane-stabilizing, antimicrobial and reparative activity will allow forming the pharmacological profile of ECSH as a potential phleboprotective drug.

show abstract

Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review

Cited by 25 publications

References 74 publications

Drug‐coated balloon therapy for in‐stent restenosis in patients with iliofemoral deep vein thrombosis: A single‐arm observational study

Drug‐coated balloon therapy for in‐stent restenosis in patients with iliofemoral deep vein thrombosis: A single‐arm observational study

Optimizing Venous Stenting: Consensus Recommendations for Enhanced Management of Lower Extremity Deep Vein Thrombosis

Phleboprotective effect of Saponaria officinalis herbs extract under conditions of experimental venostasis

Contact Info

Product

Resources

About